Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · January 12, 2022

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
J. Clin. Oncol 2021 Dec 21;[EPub Ahead of Print], DM O'Malley, M Neffa, BJ Monk, T Melkadze, M Huang, A Kryzhanivska, I Bulat, TM Meniawy, A Bagameri, EW Wang, B Doger de Speville Uribe, R Hegg, W Ortuzar Feliu, M Ancukiewicz, I Lugowska

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading